| Literature DB >> 28978425 |
Ken Coppieters1, Matthias von Herrath2.
Abstract
Antigen-specific immunotherapy has long been hailed as the ideal disease-modifying approach for type 1 diabetes, both for disease prevention and reversal. A small phase 1 trial now demonstrates safety of a peptide-based treatment in recently diagnosed adults.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28978425 DOI： 10.1016/j.cmet.2017.09.016
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287